GETUG12_2: GETUG12, figure 2

GETUG12_2R Documentation

GETUG12, figure 2

Description

Kaplan-Meier digitized data from GETUG12, figure 2 (PMID 26028518). A reported sample size of 207 for a primary endpoint of RFS in prostate cancer.

Usage

GETUG12_2

Format

A data frame of 413 observations and 3 variables:

time event time (in years)
event RFS event indicator (0: no event, 1: event)
arm treatment arms (adt, adt_de)

Source

Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015; 16: 787–94.

Examples

summary(GETUG12_2)

kmplot(GETUG12_2)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.